Previous Close | 38.85 |
Open | 39.28 |
Bid | 36.42 x 2200 |
Ask | 42.00 x 800 |
Day's Range | 38.21 - 41.80 |
52 Week Range | 26.10 - 129.09 |
Volume | |
Avg. Volume | 1,506,737 |
Market Cap | 3.985B |
Beta (5Y Monthly) | 1.23 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.89 |
Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 85.20 |
Subscribe to Yahoo Finance Plus to view Fair Value for NTRA
Natera, Inc. ( NASDAQ:NTRA ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has presented data on the clinical utility of the company's Prospera™ and Renasight™ tests in 14 sessions at the American Transplant Congress (ATC) 2022 meeting. This expands on the thirteen peer-reviewed papers that have been published over the last twelve months, demonstrating the strong performance of both assays.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the 2022 ASCO® Annual Meeting taking place June 3 – 7, 2022.